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Abstract: Urticaria is a heterogeneous group of disorders, especially
acute urticaria and angiooedema can be a medical emergency. This
paper summarizes the EAACI/GA2LEN/EDF/WAO guidelines, the
most recent international guidelines from 2009. Patients with urti-
caria are often not diagnosed and treated appropriately and the guide-
lines state that clinicians should always aim to provide complete
symptom relief. The mainstay of urticaria treatment is the use of
modern nonsedating antihistamines, if required up to 4-fold of stan-
dard doses.
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Urticaria is a common, heterogeneous group of disorderswith a large variety of underlying causes. It is character-
ized by the appearance of ﬂeeting wheals, which each last
1–24 hours and/or angioedema lasting up to 72 hours. This
paper summarizes the EAACI/GA2LEN/EDF/WAO guidelines
from 20091,2 for an outline of the diagnosis and treatment of
the disease. Currently, these are the only international guide-
lines available. These guidelines are the result of a consensus
reached during a panel discussion at the 3rd International
Consensus Meeting on Urticaria, Urticaria 2008, a joint ini-
tiative of the Dermatology Section of the European Academy
of Allergology and Clinical Immunology (EAACI), the EU-
funded network of excellence, the Global Allergy and Asthma
European Network (GA2LEN), the European Dermatology
Forum (EDF), and the World Allergy Organization (WAO).
CLASSIFICATION OF URTICARIA ON THE BASIS
OF ITS DURATION, FREQUENCY, AND CAUSES
The spectrum of clinical manifestations of different
urticaria subtypes is very wide. Additionally, 2 or more dif-
ferent subtypes of urticaria can coexist in any given patient.
Table 1 presents a classiﬁcation for clinical use.
Another important factor the new guidelines point out
is assessing disease activity. Where physical triggers are
implicated an exact measurement of the intensity of the
eliciting factor can be made, for example, the temperature and
duration of application in cold urticaria or pressure, and
the duration of application until provocation of lesions in
delayed pressure urticaria. For nonphysical acute and chronic
urticaria, assessing disease activity is more complex. The
TABLE 1. Assessment of Disease Activity in Urticaria Patients
Score Wheals Pruritus
0 None None
1 Mild (,20 wheals/
24 hours)
Mild (present but not annoying or
troublesome)
2 Moderate (20–50 wheals/
24 hours)
Moderate (troublesome but does
not interfere with normal daily
activity or sleep
3 Intense (.50 wheals/24
hours or large conﬂuent
areas of wheals)
Intense (severe pruritus, which is
sufﬁciently troublesome to
interfere with normal daily
activity or sleep)
Sum of score: 0–6.
TABLE 2. Suggested Questions
Number Question
1 Time of onset of disease
2 Frequency and duration of wheals
3 Diurnal variation
4 Occurrence in relation to weekends, holidays, and foreign travel
5 Shape, size, and distribution of wheals
6 Associated angioedema
7 Associated subjective symptoms of lesion, e.g. itch, pain
8 Family and personal history regarding urticaria, atopy
9 Previous or current allergies, infections, internal diseases, or
other possible causes
10 Psychosomatic and psychiatric diseases
11 Surgical implantations and events during surgery
12 Gastric/intestinal problems (stool, ﬂatulence)
13 Induction by physical agents or exercise
14 Use of drugs (NSAIDs, injections, immunizations, hormones,
laxatives, suppositories, ear and eye drops, and alternative
remedies)
15 Observed correlation to food
16 Relationship to the menstrual cycle
17 Smoking habits
18 Type of work
19 Hobbies
20 Stress (eustress and distress)
21 Quality of life related to urticaria and emotional impact
22 Previous therapy and response to therapy
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guidelines propose using scales from 0 to 3. This simple
scoring system (Table 1) is based on the assessment of key
urticaria symptoms (wheals and pruritus). It is also suitable
for evaluation of disease activity by urticaria patients and
their treating physicians and it has been validated.3
As urticaria symptoms frequently change in intensity
during the course of a day, overall disease activity is best
measured by advising patients to document 24-hour self-
evaluation scores for several days.
DIAGNOSIS OF URTICARIA
Because of the heterogeneity of urticaria and its many
subtypes, guidelines for diagnosis might start with a routine
patient evaluation, which should comprise a thorough history
and physical examination, and the ruling out of severe
systemic disease by basic laboratory tests. Speciﬁc provoca-
tion and laboratory tests should be carried out on an
individualized basis on the basis of the suspected cause.
Of all the diagnostic procedures, the most important is to
obtain a thorough history including all possible eliciting factors
and signiﬁcant aspects of the nature of the urticaria. Questions
suggested by the guidelines are summarized in Table 2.
The second step is physical examination of the patient.
This should include a test for dermographism. Subsequent
diagnostic steps will depend on the nature of the urticaria
subtype, as summarized in Table 3.
TREATMENT OF URTICARIA
Omission of Eliciting Drugs
Common drugs eliciting and aggravating chronic
spontaneous urticaria include nonsteroidal anti-inﬂammatory
drugs and angiotensin-converting enzyme inhibitors.1,2 If
TABLE 3. Recommended Diagnostic Tests in Frequent Urticaria Subtypes
Types Subtypes Routine Diagnostic Tests (Recommended)
Extended Diagnostic Programme (Suggested) for
Identiﬁcation of Eliciting Factors and for Ruling








Differential blood count and ESR or
CRP omission of suspected drugs
(e.g. NSAID)
Test for (i) infectious diseases (e.g. Helicobacter
pylon); (ii) type I allergy; (iii) functional
autoantibodies; (iv) thyroid hormones and
autoantibodies; (v) skin tests including physical
tests; (vi) pseudoallergen-free diet for 3 weeks and






Cold provocation and threshold test
(ice cube, cold water, cold wind)
Differential blood count and ESR/CRP cryoproteins
rule out other diseases, especially infections
Delayed pressure
urticaria
Pressure test (0.2–1.5 kg/cm² for
10 and 20 minutes)
None
Heat contact urticaria Heat provocation and threshold test (warm water) None
Solar urticaria UV and visible light of different wave lengths Rule out other light-induced dermatoses
Demographic urticaria/
urticaria factitia
Elicit demographism Differential blood count, ESR/CRP
Other urticaria
types
Aquagenic urticaria Wet cloths at body temperature applied for
20 minutes
None
Cholinergic urticaria Exercise and hot bath provocation None
Contact urticaria Prick/patch test read after 20 minutes None
Exercise-induced
anaphylaxis/urticaria
According to history exercise test with/without
food but not after a hot bath
None
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, nonsteroidal anti-inﬂammatory drugs.
Depending on suspected cause.
Unless strongly suggested by patient history, e.g. allergy.
As indication of severe systemic disease.
FIGURE 1. Taken from EAACI/GA2LEN/EDF/WAO Guideline:
Management of Urticaria.
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Alternatives (for Patients Who Do Not










ns sg H1-AH: l Low Strong Prednisolone, 2 x 20 mg/d* for 4 days Low Weak
Prednisolone, 50 mg/d* for 3 days Very low




ns sg H1-AH High Strong ns sg H1-AH and ciclosporin High All weak














ns sg H1-AH and stanazolol Low
ns sg H1-AH and zaﬁrlukast Very low
ns sg H1-AH and mycophenolate mofetil Very low
ns sg H1-AH and narrowband UV-B Very low




























c. Physical urticaria In generel for
physical urticarias:
Avoidance of stimuli




ns sg H1-AH: Low Weak Ketotifen (see also chronic
urticaria) narrowband
UV-B therapy
Very low All weak
Delayed pressure
urticaria
ns sg H1-AH: cetirizine Low All weak Combination therapy: All weak
Montelukast and ns H1-AH
(loratadine)
Very low
High dose ns H1-AH Very low Monotherapy:
Very low Prednisolone 40–20 mg* Very low
Other treatment options
Combination therapy:
Ketotifen and nimesulide Very low
(Continued)
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drugs are suspected to cause or aggravate urticaria, they
should be omitted or substituted appropriately.
Avoidance of Physical and Other Stimuli in
Inducible Urticaria
In patients suffering from inducible urticaria such as
cholinergic urticaria, solar urticaria, or cold urticaria, the avoid-
ance of the trigger should be attempted as much as possible.
Treatment of Infectious Agents
In some cases of chronic spontaneous urticaria eradica-
tion of infections, such as H. pylori, bowel parasites and bac-
terial infections of the nasopharynx, have shown to provide
a beneﬁt in the management of the disease.1,2,4,5 However, the
eradication of intestinal candida is no longer believed to be of
beneﬁt. In addition chronic inﬂammatory processes such as
gastritis, esophageal reﬂux disease and inﬂammations of the
bile duct and gall bladder are now believed to be potential
causative factors and should be managed accordingly.2,6
Dietary Modifications
If IgE-mediated food allergy has been identiﬁed as
a trigger of chronic spontaneous urticaria, the speciﬁc
allergen should be avoided as much as possible. This
should clear the symptoms within 24 to 48 hours.
Pseudoallergens can also elicit or aggravate chronic
spontaneous urticaria but, in contrast to Typ-I allergens,
need to be avoided for at least 3 to 6 months, to provide
any beneﬁt.
Symptomatic Treatment
The aim of the symptomatic therapy is to provide
complete symptom relief. In general a stepwise approach is
followed as illustrated in Figure 1.2
Nonsedating antihistamines have a very good evi-
dence for efﬁcacy, a very good safety proﬁle and are low
in cost.Increasing the dose of the second generation
antihistamines is recommended because of a good safety
proﬁle, good evidence of efﬁcacy, and low cost. Although
the third treatment step is supported by the beneﬁt of
a good safety proﬁle and low to medium-low cost, there is
no or insufﬁcient evidence for its efﬁcacy in high quality
RCTs. Corticosteroids should only be used in the treat-
ment of acute urticaria or acute ﬂares of chronic sponta-
neous urticaria. Their long-term use should be avoided
























Cold urticaria ns sg H1-AH High Strong Trial with penicillin
i.m./p.o.
Very low All weak









Solar urticaria ns H1-AH Very low Weak Induction of physical
tolerance
Very low All weak
Other treatment options
Plasmapheresis 1 PUVA Very low
Photopheresis Very low






Cholinergic urticaria ns H1-AH Low Weak “Exercise tolerance” Very low All weak
Other treatment options
- Increase dosage if
necessary, up to
fourfold
Low Ketotifen, danazol Very low
Omalizumab Very low
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refractory to any of the above measures, ciclosporin can be
used as it has an effect on mast-cell mediator release and
prevents basophil histamin release. However, because of
its medium-high costs, moderate safety, and moderate
level of evidence of efﬁcacy, its beneﬁts need to be
carefully balanced against the disadvantages. Another
option is the use of Omalizumab (anti-IgE) in some cases
of chronic spontaneous urticaria, cholinergic-, cold-, or
solar urticaria. Its high cost and low level of evidence of
efﬁcacy should be carefully considered before introducing
the medication. Furthermore, many other treatments have
been proposed like dapsone, sulfasalazine, methotrexat,
IVIG, interferon, and plasmapharesis but only been tested
in uncontrolled trials or case studies and further studies are
required to evaluate their effects. Table 4 illustrates the
evidence for commonly used drugs.
SUMMARY
The new guidelines for urticaria give clear recom-
mendations, on diagnosis and treatment. Further RCTs
are required to provide the best possible treatment to
patients, who do not respond to ﬁrst-or second line-
treatments.
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